| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 3836 | 2018 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature, 1-7, 2020 | 1674 | 2020 |
| The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy V Gopalakrishnan, BA Helmink, CN Spencer, A Reuben, JA Wargo Cancer cell 33 (4), 570-580, 2018 | 1119 | 2018 |
| Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov … PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ... J Thorac Oncol 11, S237-8, 2016 | 925* | 2016 |
| Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ... Cancer discovery, CD-15-1545, 2016 | 925 | 2016 |
| Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017; 9 W Roh, PL Chen, A Reuben, CN Spencer, PA Prieto, JP Miller, ... | 761* | |
| Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance W Roh, PL Chen, A Reuben, CN Spencer, PA Prieto, JP Miller, ... Science translational medicine 9 (379), eaah3560, 2017 | 759 | 2017 |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ... Nature medicine 24 (11), 1649, 2018 | 685 | 2018 |
| Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 532 | 2018 |
| Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised … RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ... The Lancet Oncology 19 (2), 181-193, 2018 | 270 | 2018 |
| Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration LV Johnson, DL Forest, CD Banna, CM Radeke, MA Maloney, J Hu, ... Proceedings of the National Academy of Sciences 108 (45), 18277-18282, 2011 | 211 | 2011 |
| Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma A Reuben, CN Spencer, PA Prieto, V Gopalakrishnan, SM Reddy, ... NPJ genomic medicine 2 (1), 10, 2017 | 131 | 2017 |
| Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma T Kim, RN Amaria, C Spencer, A Reuben, ZA Cooper, JA Wargo Cancer biology & medicine 11 (4), 237, 2014 | 96 | 2014 |
| The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors CN Spencer, V Gopalakrishnan, J McQuade, MC Andrews, B Helmink, ... Cancer Research 79 (13 Supplement), 2838-2838, 2019 | 80 | 2019 |
| Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma ZA Cooper, A Reuben, CN Spencer, PA Prieto, JL Austin-Breneman, ... Oncoimmunology 5 (3), e1136044, 2016 | 61 | 2016 |
| Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: a pilot study Y Qin, M Petaccia de Macedo, A Reuben, MA Forget, C Haymaker, ... Oncoimmunology 6 (6), e1321187, 2017 | 50 | 2017 |
| Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similariti es and differences: A pilot study. Y Qin, M Petaccia de Macedo, A Reuben, MA Forget, C Haymaker, ... | 50 | 2017 |
| Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. JA Wargo, V Gopalakrishnan, C Spencer, T Karpinets, A Reuben, ... Journal of Clinical Oncology 35 (15_suppl), 3008-3008, 2017 | 36 | 2017 |
| Nurse and patient characteristics predict communication about complementary and alternative medicine CN Spencer, G Lopez, L Cohen, DL Urbauer, DM Hallman, MJ Fisch, ... Cancer 122 (10), 1552-1559, 2016 | 24 | 2016 |
| Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. V Gopalakrishnan, C Spencer, A Reuben, T Karpinets, D Hutchinson, ... Journal of Clinical Oncology 35 (7_suppl), 2-2, 2017 | 22 | 2017 |
